市場調查報告書

基因治療的全球市場:市場規模·佔有率·趨勢分析

Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type, By Region, And Segment Forecasts, 2020 - 2027

出版商 Grand View Research, Inc. 商品編碼 656116
出版日期 內容資訊 英文 160 Pages
商品交期: 2-3個工作天內
價格
基因治療的全球市場:市場規模·佔有率·趨勢分析 Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Acute Lymphoblastic Leukemia, Large B-cell Lymphoma), By Vector Type, By Region, And Segment Forecasts, 2020 - 2027
出版日期: 2020年02月28日內容資訊: 英文 160 Pages
簡介

本報告提供全球基因治療市場調查,提供市場概要,各產品·媒介類型·各地區的市場規模的變化與預測,市場成長要素及阻礙因素,市場機會,市場佔有率,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 摘要整理

第2章 調查手法

  • 資訊採購
  • 資料分析
  • 市場定式化與檢驗

第3章 市場變數·趨勢·範圍

  • 前幾名市場分析
  • 市場動態
  • 普及率與成長預測
  • SWOT分析
  • 波特的五力分析

第4章 全球基因治療市場:各產品

  • 市場趨勢分析:各產品
    • 急性淋巴芽球性白血病
    • 遺傳性視網膜疾病
    • 大型B細胞淋巴瘤
    • 腺苷脫氨酶
    • 黑色素瘤
    • 鐮狀細胞貧血
    • 頭頸部鱗狀細胞癌
    • 末梢動脈疾患
    • 脊髓性肌萎縮症
    • 其他

第5章 全球基因治療市場:各載體類型

  • 市場趨勢分析:各載體類型
    • 慢病毒
    • 腺結合病毒
    • 反轉錄病毒 & 伽馬反轉錄病毒
    • 變性單純皰疹病毒
    • 腺病毒
    • 非病毒性質體媒介

第6章 全球基因治療市場:各地區

  • 市場趨勢分析:各地區
    • 北美
    • 歐洲
    • 亞太地區

第7章 競爭情形

  • 策略架構
    • Novartis AG
    • Bluebird bio, Inc.
    • Spark Therapeutics, Inc.
    • REGENXBIO, Inc.
    • Audentes Therapeutics
    • Voyager Therapeutics
    • Oxford BioMedica plc
    • Human Stem Cells Institute
    • Dimension Therapeutics, Inc.
    • Bristol-Myers Squibb Company
    • Sanofi
    • Applied Genetic Technologies Corporation
    • Taxus Cardium Pharmaceuticals Group, Inc.
    • UniQure N.V.
    • Celgene Corporation
    • Shire Plc
    • Cellectis S.A.
    • Sangamo Therapeutics, Inc.
    • Orchard Therapeutics
    • Gilead Lifesciences, Inc.
    • Benitec Biopharma
    • Sibiono GeneTech Co., Ltd
    • Shanghai Sunway Biotech Co., Ltd.
    • Gensight Biologics S.A.
    • Transgene
    • Epeius Biotechnologies Corp.
    • Calimmune, Inc.
    • Audentes Therapeutics, Inc.
    • American Gene Technologies
    • BioMarin Pharmaceuticals, Inc.

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GVR-2-68038-179-5

The global gene therapy market size is expected to reach USD 6.6 billion by 2027, at a CAGR of 16.6% over the forecast period, according to a new report by Grand View Research, Inc. The approval of early CAR-T-based gene therapy products has created lucrative avenues in product approvals over expanded indications. Clinical trials for T-cell therapies each year has risen exponentially in the recent past. Constant developments in CAR-T cell therapy are recognized as one of the key driving factors for market growth.

Although gene therapy has primarily been used for cancer treatment, it increasingly finds application in the treatment of various rare and incurable diseases. Approval of products for non-cancer applications, such as approval of Bluebird Bio's Zynteglo in June 2019 for B-thalassemia, indicates the shift in preferences of companies toward other untapped segments.

Gene therapies involve complex molecules and hence manufacturing these molecules is a challenge for developers, particularly in with regard to specialized manufacturing facilities and highly skilled technical personnel. This has created lucrative avenues for contract service providers operating in the space.

Further key findings from the study suggest:

Since viral vectors are the most conventional method for the delivery of genes, several operating players have designed their gene therapy programs based on viral vectors

In 2019, the lentivirus and retrovirus generated significant revenue owing to the approval of lentivirus-based Kymriah and retrovirus-based Yescarta in 2017 by the U.S. FDA

Among various indications, a majority of the revenue share is generated by various forms of cancer. This is attributed to the presence of approved products for cancer forms such as acute lymphoblastic leukemia (ALL), large B-cell lymphoma, and melanoma

North America dominated the global gene therapy market in 2019 as U.S. is the largest market for clinical trials related to gene therapy, since around 60.0% of all clinical trials in the world are carried out in the country. Moreover, FDA approval of Kymriah and Yescarta in U.S. in 2017 and Kymriah in Canada in 2018 has resulted in huge investments by sponsors and government agencies in North America

Key market players include Bluebird Bio, Novartis AG, UniQure NV, Gilead Sciences, Spark Therapeutics LLC, and Celgene Corporation

These players are engaged in signing licensing, commercialization, and development agreements with other market participants to expand their business operations in cell and gene therapy domain. For instance, Novartis Pharmaceuticals received commercialization rights for Spark Therapeutics' Luxturna for selling the product outside U.S.

Table of Contents

Chapter 1 Executive Summary

  • 1.1 Market Snapshot

Chapter 2 Research Methodology

  • 2.1 Information Procurement
  • 2.2 Information or Data Analysis
  • 2.3 Market Formulation & Validation

Chapter 3 Gene Therapy Market Variables, Trends & Scope

  • 3.1 Market Segmentation & Scope
    • 3.1.1 Market driver analysis
      • 3.1.1.1 Robust gene therapy pipeline
      • 3.1.1.2 Introduction of technological advancements
      • 3.1.1.3 Increasing investment from the companies and partnerships
      • 3.1.1.4 Growing prevalence of target diseases and increased demand for innovative medicine
    • 3.1.2 Market restraint analysis
      • 3.1.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
      • 3.1.2.2 High prices of gene therapy medicines
    • 3.1.3 Opportunity analysis
      • 3.1.3.1 Rising investment for adoptive T cell transfer approaches of disease treatment
      • 3.1.3.2 Facility expansion for cell and gene therapies
      • 3.1.3.3 Technological advancements in manufacturing vectors
    • 3.1.4 Challenge Analysis
      • 3.1.4.1 Production capacity challenges
      • 3.1.4.2 Manufacturing challenges pertaining to large-scale production of vectors
    • 3.1.5 Regulatory framework
  • 3.2 Gene Therapy Market - SWOT Analysis, By Factor (Political & legal, economic and technological)
  • 3.3 Industry Analysis - Porter's
  • 3.4 Pricing Analysis
  • 3.5 Pipeline Analysis

Chapter 4 Gene Therapy Market Categorization: Indication Estimates & Trend Analysis

  • 4.1 Gene Therapy Market: Indication Movement Analysis
  • 4.2 Acute Lymphoblastic Leukemia (ALL)
    • 4.2.1 Global gene therapy market for Acute Lymphoblastic Leukemia (ALL), 2016 - 2027 (USD Million)
  • 4.3 Inherited Retinal Disease
    • 4.3.1 Global gene therapy market for inherited retinal disease, 2016 - 2027 (USD Million)
  • 4.4 Large B-cell Lymphoma
    • 4.4.1 Global gene therapy market for large B-cell lymphoma, 2016 - 2027 (USD Million)
  • 4.5 Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)
    • 4.5.1 Global gene therapy market for ADA-SCID, 2016 - 2027 (USD Million)
  • 4.6 Melanoma (Lesions)
    • 4.6.1 Global gene therapy market for melanoma (lesions), 2016 - 2027 (USD Million)
  • 4.7 Beta-Thalassemia Major/Sickle Cell Disease (SCD)
    • 4.7.1 Global gene therapy market for Beta-Thalassemia Major/SCD, 2016 - 2027 (USD Million)
  • 4.8 Head & Neck Squamous Cell Carcinoma
    • 4.8.1 Global gene therapy market for head & neck squamous cell carcinoma, 2016 - 2027 (USD Million)
  • 4.9 Peripheral Arterial Disease
    • 4.9.1 Global gene therapy market for peripheral arterial disease, 2016 - 2027 (USD Million)
  • 4.10 Spinal Muscular Atrophy (SMA)
    • 4.10.1 Global gene therapy market for Spinal Muscular Atrophy (SMA), 2016 - 2027 (USD Million)
  • 4.11 Others
    • 4.11.1 Global gene therapy market for other indications, 2016 - 2027 (USD Million)

Chapter 5 Gene Therapy Market Categorization: Vector Type Estimates & Trend Analysis

  • 5.1 Gene Therapy Market: Vector Type Movement Analysis
  • 5.2 Lentivirus
    • 5.2.1 Global lentivirus-based gene therapy market, 2016 - 2027 (USD Million)
  • 5.3 AAV
    • 5.3.1 Global AAV-based gene therapy market, 2016 - 2027 (USD Million)
  • 5.4 Retrovirus & Gammaretrovirus
    • 5.4.1 Global Retrovirus & Gammaretrovirus vectors-based gene therapy market, 2016 - 2027 (USD Million)
  • 5.5 Modified Herpes Simplex Virus
    • 5.5.1 Global modified herpes simplex virus vectors-based gene therapy market, 2016 - 2027 (USD Million)
  • 5.6 Adenovirus
    • 5.6.1 Global adenovirus vectors-based gene therapy market, 2016 - 2027 (USD Million)
  • 5.7 Non-viral Plasmid Vectors
    • 5.7.1 Global non-viral plasmids-based gene therapy market, 2016 - 2027 (USD Million)

Chapter 6 Gene Therapy Market Regional Estimates & Trend Analysis, by Indication and Vector Type

  • 6.1 Gene Therapy Market Share, By Region
  • 6.2 North America
    • 6.2.1 North America gene therapy market, 2016 - 2027 (USD Million)
    • 6.2.2 U.S.
      • 6.2.2.1 U.S. gene therapy market, by indication, 2016 - 2027 (USD Million)
      • 6.2.2.2 U.S. gene therapy market, by vector type, 2016 - 2027 (USD Million)
    • 6.2.3 Canada
      • 6.2.3.1 Canada gene therapy market, by indication, 2016 - 2027 (USD Million)
      • 6.2.3.2 Canada gene therapy market, by vector type, 2016 - 2027 (USD Million)
  • 6.3 Europe
    • 6.3.1 Europe gene therapy market, 2016 - 2027 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific gene therapy market, 2016 - 2027 (USD Million)
    • 6.4.2 China
      • 6.4.2.1 China gene therapy market, by indication, 2016 - 2027 (USD Million)
      • 6.4.2.2 China gene therapy market, by vector type, 2016 - 2027 (USD Million)
    • 6.4.3 Japan
      • 6.4.3.1 Japan gene therapy market, by indication, 2016 - 2027 (USD Million)
      • 6.4.3.2 Japan gene therapy market, by vector type, 2016 - 2027 (USD Million)
    • 6.4.4 Russia
      • 6.4.4.1 Russia gene therapy market, by indication, 2016 - 2027 (USD Million)
      • 6.4.4.2 Russia gene therapy market, by vector type, 2016 - 2027 (USD Million)
    • 6.4.5 Australia
      • 6.4.5.1 Australia gene therapy market, by indication, 2016 - 2027 (USD Million)
      • 6.4.5.2 Australia gene therapy market, by vector type, 2016 - 2027 (USD Million)

Chapter 7 Competitive Landscape

  • 7.1 Strategy Framework
    • 7.1.1 Novartis AG
    • 7.1.2 Bluebird bio, Inc.
    • 7.1.3 Spark Therapeutics, Inc.
    • 7.1.4 REGENXBIO, Inc.
    • 7.1.5 Audentes Therapeutics
    • 7.1.6 Voyager Therapeutics
    • 7.1.7 REGENXBIO, Inc.
      • 7.1.7.1 Company overview
      • 7.1.7.2 Financial performance
      • 7.1.7.3 Product benchmarking
      • 7.1.7.4 Strategic initiatives
    • 7.1.8 Oxford BioMedica plc
      • 7.1.8.1 Company overview
      • 7.1.8.2 Financial performance
      • 7.1.8.3 Product benchmarking
      • 7.1.8.4 Strategic initiatives
    • 7.1.9 Voyager Therapeutics
      • 7.1.9.1 Company overview
      • 7.1.9.2 Financial performance
      • 7.1.9.3 Product benchmarking
      • 7.1.9.4 Strategic initiatives
    • 7.1.10 Human Stem Cells Institute
      • 7.1.10.1 Company overview
      • 7.1.10.2 Financial performance
      • 7.1.10.3 Product benchmarking
      • 7.1.10.4 Strategic initiatives
    • 7.1.11 Dimension Therapeutics, Inc.
      • 7.1.11.1 Company overview
      • 7.1.11.2 Financial performance
      • 7.1.11.3 Product benchmarking
      • 7.1.11.4 Strategic initiatives
    • 7.1.12 Bristol-Myers Squibb Company
      • 7.1.12.1 Company overview
      • 7.1.12.2 Financial performance
      • 7.1.12.3 Product benchmarking
      • 7.1.12.4 Strategic initiatives
    • 7.1.13 Sanofi
      • 7.1.13.1 Company overview
      • 7.1.13.2 Financial performance
      • 7.1.13.3 Product benchmarking
      • 7.1.13.4 Strategic initiatives
    • 7.1.14 Applied Genetic Technologies Corporation
      • 7.1.14.1 Company overview
      • 7.1.14.2 Financial performance
      • 7.1.14.3 Product benchmarking
      • 7.1.14.4 Strategic initiatives
    • 7.1.15 Spark Therapeutics, Inc.
      • 7.1.15.1 Company overview
      • 7.1.15.2 Financial performance
      • 7.1.15.3 Product benchmarking
      • 7.1.15.4 Strategic initiatives
    • 7.1.16 Bluebird Bio, Inc.
      • 7.1.16.1 Company overview
      • 7.1.16.2 Financial performance
      • 7.1.16.3 Product benchmarking
      • 7.1.16.4 Strategic initiatives
    • 7.1.17 Novartis AG
      • 7.1.17.1 Company overview
      • 7.1.17.1.1 AveXis, Inc.
      • 7.1.17.2 Financial performance (Novartis AG)
      • 7.1.17.2.1 Financial performance (AveXis, Inc.)
      • 7.1.17.3 Product benchmarking
      • 7.1.17.4 Strategic initiatives (Novartis AG)
      • 7.1.17.4.1 Strategic initiatives (AveXis, Inc.)
    • 7.1.18 Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
      • 7.1.18.1 Company overview
      • 7.1.18.2 Financial performance
      • 7.1.18.3 Product benchmarking
      • 7.1.18.4 Strategic initiatives
    • 7.1.19 UniQure N.V.
      • 7.1.19.1 Company overview
      • 7.1.19.2 Financial performance
      • 7.1.19.3 Product benchmarking
      • 7.1.19.4 Strategic initiatives
    • 7.1.20 Celgene Corporation
      • 7.1.20.1 Company overview
      • 7.1.20.2 Financial performance
      • 7.1.20.3 Product benchmarking
      • 7.1.20.4 Strategic initiatives
    • 7.1.21 Shire Plc
      • 7.1.21.1 Company overview
      • 7.1.21.2 Financial performance
      • 7.1.21.3 Product benchmarking
      • 7.1.21.4 Strategic initiatives
    • 7.1.22 Cellectis S.A.
      • 7.1.22.1 Company overview
      • 7.1.22.2 Financial performance
      • 7.1.22.3 Product benchmarking
      • 7.1.22.4 Strategic initiatives
    • 7.1.23 Sangamo Therapeutics, Inc.
      • 7.1.23.1 Company overview
      • 7.1.23.2 Financial performance
      • 7.1.23.3 Product benchmarking
      • 7.1.23.4 Strategic initiatives
    • 7.1.24 Orchard Therapeutics
      • 7.1.24.1 Company Overview
      • 7.1.24.2 Product Benchmarking
      • 7.1.24.3 Strategic initiatives
    • 7.1.25 Gilead Lifesciences, Inc.
      • 7.1.25.1 Company Overview
      • 7.1.25.2 Financial Performance
      • 7.1.25.3 Product Benchmarking
      • 7.1.25.4 Strategic initiatives
    • 7.1.26 Benitec Biopharma
      • 7.1.26.1 Company overview
      • 7.1.26.2 Financial performance
      • 7.1.26.3 Product benchmarking
      • 7.1.26.4 Strategic initiatives
    • 7.1.27 Sibiono GeneTech Co., Ltd
      • 7.1.27.1 Company Overview
      • 7.1.27.2 Product benchmarking
    • 7.1.28 Shanghai Sunway Biotech Co., Ltd.
      • 7.1.28.1 Company overview
      • 7.1.28.2 Product benchmarking
    • 7.1.29 Gensight Biologics S.A.
      • 7.1.29.1 Company overview
      • 7.1.29.2 Financial performance
      • 7.1.29.3 Product benchmarking
      • 7.1.29.4 Strategic initiatives
    • 7.1.30 Transgene
      • 7.1.30.1 Company overview
      • 7.1.30.2 Financial performance
      • 7.1.30.3 Product benchmarking
      • 7.1.30.4 Strategic initiatives
    • 7.1.31 Epeius Biotechnologies Corp.
      • 7.1.31.1 Company overview
      • 7.1.31.2 Financial performance
      • 7.1.31.3 Product benchmarking
    • 7.1.32 Calimmune, Inc.
      • 7.1.32.1 Company overview
      • 7.1.32.2 Product benchmarking
      • 7.1.32.3 Strategic initiatives
    • 7.1.33 Audentes Therapeutics, Inc.
      • 7.1.33.1 Company overview
      • 7.1.33.2 Financial performance
      • 7.1.33.3 Product benchmarking
      • 7.1.33.4 Strategic initiatives
    • 7.1.34 American Gene Technologies
      • 7.1.34.1 Company overview
      • 7.1.34.2 Product Benchmarking
    • 7.1.35 BioMarin Pharmaceuticals, Inc.
      • 7.1.35.1 Company overview
      • 7.1.35.2 Financial performance
      • 7.1.35.3 Product benchmarking
      • 7.1.35.4 Strategic initiatives

List of Tables

  • TABLE 1 Ongoing projects for CAR T-cell therapies
  • TABLE 2 Non-viral DNA vectors (non-replicating) in gene therapy trials
  • TABLE 3 Some of the examples of molecules under development based on lentiviral vectors
  • TABLE 4 Molecules in development based on AAV vectors
  • TABLE 5 North America gene therapy market, by indication, 2016 - 2027 (USD Million)
  • TABLE 6 North America gene therapy market, by vector type, 2016 - 2027 (USD Million)
  • TABLE 7 U.S. gene therapy market, by indication, 2016 - 2027 (USD Million)
  • TABLE 8 U.S. gene therapy market, by vector type, 2016 - 2027 (USD Million)
  • TABLE 9 Canada gene therapy market, by indication, 2016 - 2027 (USD Million)
  • TABLE 10 Canada gene therapy market, by vector type, 2016 - 2027 (USD Million)
  • TABLE 11 Europe gene therapy market, by indication, 2016 - 2027 (USD Million)
  • TABLE 12 Europe gene therapy market, by vector type, 2016 - 2027 (USD Million)
  • TABLE 13 Asia Pacific gene therapy market, by indication, 2016 - 2027 (USD Million)
  • TABLE 14 Asia Pacific gene therapy market, by vector type, 2016 - 2027 (USD Million)
  • TABLE 15 China gene therapy market, by indication, 2016 - 2027 (USD Million)
  • TABLE 16 China gene therapy market, by vector type, 2016 - 2027 (USD Million)
  • TABLE 17 Japan gene therapy market, by indication, 2016 - 2027 (USD Million)
  • TABLE 18 Japan gene therapy market, by vector type, 2016 - 2027 (USD Million)
  • TABLE 19 Russia gene therapy market, by indication, 2016 - 2027 (USD Million)
  • TABLE 20 Russia gene therapy market, by vector type, 2016 - 2027 (USD Million)
  • TABLE 21 Australia gene therapy market, by indication, 2016 - 2027 (USD Million)
  • TABLE 22 Australia gene therapy market, by vector type, 2016 - 2027 (USD Million)

List of Figures

  • FIG. 1 Market summary (USD Million)
  • FIG. 2 Market research process
  • FIG. 3 Information procurement
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value chain based sizing & forecasting
  • FIG. 7 QFD modelling for market share assessment
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Global gene therapy pipeline as of 2017, by phase of trial
  • FIG. 12 Global cancer incidence, as of September 2018
  • FIG. 13 Market restraint relevance analysis (Current & future impact)
  • FIG. 14 Gene therapy prices by eligible patients per year
  • FIG. 15 Annual Investment in the CAR-T Space, 2013 - 2026
  • FIG. 16 Global financings in cell therapy, 2016-2018
  • FIG. 17 Recent and ongoing manufacturing capacity expansions for viral vector and large-scale cell therapies, as of 2017
  • FIG. 18 SWOT Analysis, By Factor (Political & legal, economic and technological)
  • FIG. 19 Porter's Five Forces Analysis
  • FIG. 20 Gene therapy market: Indication outlook key takeaways
  • FIG. 21 Gene therapy market: Indication movement analysis
  • FIG. 22 Global gene therapy market for Acute Lymphoblastic Leukemia (ALL), 2016 - 2027 (USD Million)
  • FIG. 23 Global gene therapy market for inherited retinal disease, 2016 - 2027 (USD Million)
  • FIG. 24 Global gene therapy market for large B-cell lymphoma, 2016 - 2027 (USD Million)
  • FIG. 25 Global gene therapy market for ADA-SCID, 2016 - 2027 (USD Million)
  • FIG. 26 Global gene therapy market for melanoma (lesions), 2016 - 2027 (USD Million)
  • FIG. 27 Global gene therapy market for Beta-Thalassemia Major/SCD, 2016 - 2027 (USD Million)
  • FIG. 28 Global gene therapy market for head & neck squamous cell carcinoma, 2016 - 2027 (USD Million)
  • FIG. 29 Global gene therapy market for peripheral arterial disease, 2016 - 2027 (USD Million)
  • FIG. 30 Global gene therapy market for Spinal Muscular Atrophy (SMA), 2016 - 2027 (USD Million)
  • FIG. 31 Global gene therapy market for other indications, 2016 - 2027 (USD Million)
  • FIG. 32 Gene therapy market vector type outlook: Key takeaways
  • FIG. 33 Gene therapy market: Vector type movement analysis
  • FIG. 34 Global lentivirus-based gene therapy market, 2016 - 2027 (USD Million)
  • FIG. 35 Global AAV-based gene therapy market, 2016 - 2027 (USD Million)
  • FIG. 36 Global retrovirus and gammaretrovirus vector-based gene therapy market, 2016 - 2027 (USD Million)
  • FIG. 37 Global modified herpes simplex virus vectors-based gene therapy market, 2016 - 2027 (USD Million)
  • FIG. 38 Global adenovirus vectors-based gene therapy market, 2016 - 2027 (USD Million)
  • FIG. 39 Global non-viral plasmid vector-based gene therapy market, 2016 - 2027 (USD Million)
  • FIG. 40 Regional market place: Key takeaways
  • FIG. 41 Stem cells & non-stem cells regional outlook, 2019 & 2027
  • FIG. 42 North America gene therapy market, 2016 - 2027 (USD Million)
  • FIG. 43 U.S. gene therapy market, 2016 - 2027 (USD Million)
  • FIG. 44 Canada gene therapy market, 2016 - 2027 (USD Million)
  • FIG. 45 Europe gene therapy market, 2016 - 2027 (USD Million)
  • FIG. 46 Asia Pacific gene therapy market, 2016 - 2027 (USD Million)
  • FIG. 47 China gene therapy market, 2016 - 2027 (USD Million)
  • FIG. 48 Japan gene therapy market, 2016 - 2027 (USD Million)
  • FIG. 49 Russia gene therapy market, 2016 - 2027 (USD Million)
  • FIG. 50 Australia gene therapy market, 2016 - 2027 (USD Million)
  • FIG. 51 Strategy framework